Atrial Fibrillation in Patients with Cryptogenic Stroke Gladstone DJ et al. N Engl J Med 2014; 370:2467-2477 Presented by Kris Huston | July 21, 2014.

Slides:



Advertisements
Similar presentations
A Comparison of Early Versus Late Initiation of Renal Replacement Therapy in Critically III Patients with Acute Kidney Injury: A Systematic Review and.
Advertisements

New England Journal of Medicine October 18;367: Relapse Risk after Discontinuation of Risperidone in Alzheimer’s disease Molly Moncrieff.
Update on Anti-platelets Gabriel A. Vidal, MD Vascular Neurology Ochsner Medical Center October 14 th, 2009.
Widimsky P, Tousek P, Rokyta R, et al. Charles University Prague, CZ PRAGUE-7 Study (Hot Lines presenter)
A Randomized Multicenter Comparison of Radiofrequency Ablation and Antiarrhythmic Drug Therapy as First Line Treatment in 294 Patients with Paroxysmal.
J. Stephen Huff, MD, FACEP Transient Ischemic Attack Patient Update: The Optimal Management of Emergency Department Patients With Suspected Cerebral Ischemia.
Study by: Granger et al. NEJM, September 2011,Vol No. 11 Presented by: Amelia Crawford PA-S2 Apixaban versus Warfarin in Patients with Atrial Fibrillation.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2009.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2010.
TOTAL Stroke in the TOTAL trial: Randomized trial of manual aspiration Thrombectomy in STEMI TOTAL Trial Investigators.
ESUS: Embolic Strokes of Undetermined Source
Ablation for Paroxysmal Atrial Fibrillation (APAF) Trial Presented at The American College of Cardiology Scientific Session 2006 Presented by Dr. Carlo.
ICD FOR PRIMARY PREVENTION EVIDENCE REVIEW
Reference Cooper BA, and the IDEAL study group. A randomized controlled trial of early versus late initiation of dialysis. N Engl J Med [Accessed.
Journal Club Ani Balmanoukian and Peter Benjamin November 9, 2006 Journal Club Ani Balmanoukian and Peter Benjamin November 9, 2006.
An Emergency Department Diagnostic Protocol For Patients With Transient Ischemic Attack: A Randomized Controlled Trial Michael A. Ross MD Scott Compton.
OVBIAGELE B, DIENER H-C, YUSUF S, ET AL., PROFESS INVESTIGATORS. LEVEL OF SYSTOLIC BLOOD PRESSURE WITHIN THE NORMAL RANGE AND RISK OF RECURRENT STROKE.
FERNE/EMRA The Management of ED TIA Patients: What is the optimal outpatient work-up, treatment and disposition?
Discussion Gitanjali Batmanabane MD PhD. Do you look like this?
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Secondary prevention after a TIA or ischemic stroke.
Randomized, double-blind, multicenter, controlled trial.
Silent Ischemia STABLE CAD
Critical Appraisal Did the study address a clearly focused question? Did the study address a clearly focused question? Was the assignment of patients.
Terutroban versus aspirin in Patients with Cerebral Ischaemic Events (PREFORM): a Randomized, Double- blind Parallel-group Trial Daniel Wells Mercer University.
SPARCL Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.
Jim Hoehns, Pharm.D.. Lancet 2013;382: Albers G et al. Chest. 2001; 119 (suppl): 300S. Ischemic stroke 85% Hemorrhagic stroke 15% Other 5% Cryptogenic.
Clinical Trial Results. org SAGE Trial Prakash Deedwania, MD; Peter H. Stone, MD; C. Noel Bairey Merz, MD; Juan Cosin-Aguilar, MD; Nevres Koylan, MD; Don.
HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.
VBWG In-hospital course of stroke patients with vs without AF Steger C et al. Eur Heart J. 2004;6:in press. More severe stroke on admission Lower Barthel.
Grace Thacker Xavier University of Louisiana LSUHC – Internal Medicine
Κρυπτογενή εγκεφαλικά έμφρακτα Γεώργιος Ντάιος Παθολογική Κλινική, Πανεπιστήμιο Θεσσαλίας.
A-4 Trial Presented at The Heart Rhythm Society Meeting May 2006 Presented by Dr. Pierre Jais Atrial Fibrillation Ablation vs. Antiarrhythmic Drugs Trial.
Long-term mortality and thrombolysis therapy after a first acute ischemic stroke: gender differences. Ebrictus II Study. Authors & Affiliations Clua-Espuny.
Hypothesis: baseline risk status of the patients and proximity to a recent cardiovascular event influence the response to dual anti-platelet therapy. Patients.
Amiodarone versus Sotalol for Atrial Fibrillation N Engl J Med 2005;352: Bramah N. Singh, M.D., D.Sc., Steven N. Singh, M.D., Domenic J. Reda, Ph.D.,
The Case for Rate Control: In the Management of Atrial Fibrillation Charles W. Clogston, M.D. Cardiologist CHI St. Vincent Heart Clinic Arkansas April.
Disclosure Statement of Financial Interest
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial Aron Goldhirsch, Richard.
Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism ‘ The PADIS-PE Trial’ Nate Peyton.
ResultsIntroduction Atrial Fibrillation (AF) affects 1.2% 1 of the population and 10% of those over the age of 75 2 It is the commonest arrhythmia in primary.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Angela Aziz Donnelly April 5, 2016
Cost effectiveness of AF monitoring strategies in a post-stroke population LAUREN E. CIPRIANO JEFF HEALEY OMAR AKHTAR KAREN LEE LUCIANO A. SPOSATO APRIL.
Manesh R. Patel, M.D., Kenneth W. Mahaffey, M.D., Jyotsna Garg, M.S., Guohua Pan, Ph.D., Daniel E. Singer, M.D., Werner Hacke, M.D., Ph.D., Gunter Breithardt,
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation NEJM Aug 27, 2015.
R2. 최태웅 / Pf. 김진배. BACKGROUND  Ischemic stroke : leading causes of death and disability : cause remains unexplained after routine evaluation → Cryptogenic.
ESUS in the Athens Stroke Registry George Ntaios University of Thessaly, Larissa/Greece Barcelona, 08 June 2016.
1 R1 임준욱 Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation.
Radiofrequency Ablation as Initial Therapy in Paroxysmal Atrial Fibrillation Jens Cosedis Nielsen, M.D., D.M.Sc., Arne Johannessen, M.D., D.M.Sc., Pekka.
Cryptogenic Stroke and AF
Case 66 year old male with PMH of HTN, DM, ESRD on renal replacement TIW, stroke in 2011 with right side residual weakness, atrial fibrillation, currently.
David R. Holmes, Jr., M.D. Mayo Clinic, Rochester
SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.
AIM HIGH Niacin plus Statin to prevent vascular events
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
Monitoring Continuum ISSUE-3 Atrial Fibrillation Classification.
Setareh Omran, MD Vascular Neurology Fellow
Overall burden of AF associated with higher risk of thromboembolism and ischemic stroke An analysis of the KP-RHYTHM study, in patients with paroxysmal.
Dabigatran in myocardial injury after noncardiac surgery
Taking the "Cryptogenic" Out of Cryptogenic Stroke
Study Background and Rationale Updated October 24, 2018
Dabigatran in myocardial injury after noncardiac surgery
The Research Question Background: Question:
Taking the "Cryptogenic" Out of Cryptogenic Stroke
Flow diagram for exclusions of trials identified RCT indicates randomized controlled trial Hulten E, et al. Arch Intern Med 2006;166:
Dabigatran in myocardial injury after noncardiac surgery
Simvastatin in Patients With Prior Cerebrovascular Disease: HPS
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
Overall burden of AF associated with higher risk of thromboembolism and ischemic stroke An analysis of the KP-RHYTHM study, in patients with paroxysmal.
Presentation transcript:

Atrial Fibrillation in Patients with Cryptogenic Stroke Gladstone DJ et al. N Engl J Med 2014; 370: Presented by Kris Huston | July 21, 2014

2 EMBRACE trial 30-Day Cardiac Event Monitor Belt for Recording Atrial Fibrillation After a Cerebral Ischemic Event Multicenter, 3-year study funded by the Canadian Stroke Network

3 Background Atrial fibrillation is a major cause of stroke worldwide. Strokes due to atrial fibrillation are potentially preventable. Paroxysmal atrial fibrillation often evades detection. Many strokes have undetermined etiology (cryptogenic).

4 Cryptogenic stroke Brain infarction that is not attributable to a source of definite cardioembolism, large artery atherosclerosis, or small artery disease. Diagnosis of exclusion based on thorough investigation of other potential etiologies. Cryptogenic stroke accounts for 30 to 40 percent of ischemic strokes (and half the TIAs).

5 Primary objective To determine the diagnostic yield of a 30-day cardiac event monitor compared to a repeat 24-hour Holter monitor for detecting occult paroxysmal atrial fibrillation in patients with a recent ischemic stroke or TIA of undetermined etiology.

6 Study population 55 years or older Experienced ischemic stroke or TIA within previous 6 months No cause identified by post-stroke/TIA diagnostic workup, including ECG, 24-hr Holter, brain imaging, and echo. No history of atrial fibrillation or flutter.

7 Randomization, ECG Monitoring, and Follow-up

8 Baseline Characteristics of the Patients

9 Study design Multicenter, two-arm, unblinded, randomized controlled trial Sample size: N = 564 Participants were randomized (1:1) to receive either: (1) a 30-day event-triggered loop recorder (intervention group) or (2) a repeat 24-hour Holter monitor (control group)

10 Study design

11 Outcomes Primary: Detection of one or more episodes of atrial fibrillation or atrial flutter ≥30 seconds as assessed at the 90 day follow-up Secondary: 1) Oral anticoagulation use at 90 days 2) Atrial fibrillation lasting 2.5 minutes or longer

12 Detection of Atrial Fibrillation in the Two Monitoring Groups

13 Incremental Yield of Prolonged ECG Monitoring for the Detection of Atrial Fibrillation in Patients with Cryptogenic Stroke or TIA

14 Anticoagulant Therapy in the Two Monitoring Groups

15 Protocol Adherence Intervention group: 233/284 (82%) completed 3 or more weeks of monitoring. Among patients in whom atrial fibrillation was not detected before 30 days, 204/240 (85%) completed 3 or more weeks, and 148/240 (61.7%) completed 4 weeks.

16 Conclusions Among patients 55 years or older with a recent cryptogenic stroke or TIA, paroxysmal atrial fibrillation was common. Noninvasive ambulatory ECG monitoring for a target of 30 days significantly improved the detection of atrial fibrillation by a factor of more than five and nearly doubled the rate of anticoagulant treatment, as compared with the standard practice of short-duration ECG monitoring.

17 Author-reported Limitations Total burden of atrial fibrillation per patient could not be determined due to limited recording capacity of device Patients with large, severe strokes were underrepresented Monitoring started late (ave 75 days after index event), reducing overall sensitivity of atrial fibrillation detection 30-day time limit and noninvasive monitoring diminished diagnostic yield No comparison to age-matched controls without stroke or TIA

18 Critical Appraisal Strengths of the study Large, multicenter, well-designed RCT Good adherence in intervention group Device manufacturers had no role in the trial Results have potentially important clinical implications

19 Critical Appraisal Weaknesses of the study Lack of diversity in study population Did not address stroke recurrence and survival benefit Detection of atrial fibrillation is not the solution to cryptogenic stroke; need to explore other stroke etiologies Benefit of anticoagulant therapy for subclinical AF not proven Optimal duration and type of cardiac monitoring still unclear

20 CRYSTAL AF trial In this study, 441 patients with cryptogenic stroke and no evidence of atrial fibrillation during at least 24 hours of ECG monitoring were randomly assigned to prolonged ambulatory cardiac monitoring with a subcutaneous implantable loop recorder or to a control group with conventional follow-up. At six months, atrial fibrillation detection was significantly higher in the monitored group (8.9 percent, versus 1.4 percent in the control group, hazard ratio 6.4, 95% CI ). Sanna T et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med 2014; 370(26):2478

21 NEJM editorial June 26, 2014 The results of two studies published in this issue of the Journal indicate that prolonged monitoring of heart rhythm should now become part of the standard care of patients with cryptogenic stroke.